Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Analysis of the Incidence of Expression of Tumor Antigens MAGE-A3, MAGE-C2, NY-ESO-1, LAGE-1, WT1 and PRAME in Pathologically Proven Stage I, II and III Non-Small Cell Lung Cancer in Asiatic Patients

NCT01837511 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT01837511
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01837511 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Analysis of the Incidence of Expression of Tumor Antigens MAGE-A3, MAGE-C2, NY-ESO-1, LAGE-1, WT1 and PRAME in Pathologically Proven Stage I, II and III Non-Small Cell Lung Cancer in Asiatic Patients
Lead sponsor
GlaxoSmithKline
Phase
Observational
Overall status
Completed
Start date
August 31, 2007
Completion date
January 31, 2008
Enrollment
377 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

pathologically proven stage i, ii and iii non-small cell lung cancer (nsclc)